We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 42.00
Ask: 45.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.143%)
Open: 43.50
High: 43.50
Low: 42.40
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Palintest launches Molendotech bathing water test

15 May 2018 07:00

RNS Number : 9469N
Frontier IP Group plc
15 May 2018
 

RNS REACH / RNS

AIM: FIPP

15 May 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Palintest launches Molendotech bathing water test

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that Palintest, a subsidiary of FTSE 100 group Halma plc, is launching Siren BW, a water testing kit developed by portfolio company Molendotech, a spin out from the University of Plymouth.

 

It is the first commercial application for Molendotech's novel test able to identify the concentration of faecal bacteria in water. Currently, it can take two days for local authorities and environmental agencies to assess the quality of recreational water because samples must be sent to a laboratory. Palintest's field-ready kit produces a result in less than 30 minutes and is simple enough to be used at the sample point.

 

The kit is initially available in the UK and Ireland, with roll out to continental Europe and the US planned.

 

Further applications are now being developed in collaboration with Palintest to leverage the real-time availability of pathogen risk in water. It has a wide range of potential uses, including potable water and in food and beverage production.

 

Molendotech was incorporated less than a year ago to develop and commercialise the work of Simon Jackson, Professor of Environment and Human Health within the University of Plymouth's Peninsula Schools of Medicine and Dentistry.

 

Frontier IP chief executive officer Neil Crabb said: "We're delighted the agreement with Palintest, announced earlier this year, is bearing fruit so quickly. It has taken less than a year from Molendotech joining our portfolio to the commercial launch of its first product."

 

Director of Molendotech, Professor Simon Jackson, said: "Water quality is a global issue and fundamental to human and public health. Unfortunately, traditional, lab-based methods for testing water quality, particularly for faecal contamination, do not deliver the kind of rapid results required for in-situ investigation and decision-making. With this breakthrough, however, environmental agencies will be able to gain a much clearer understanding of water quality, which could lead to better and more effective management of beaches and other recreational bathing waters, and faster identification of sources of pollution."

 

Open Innovation Product Manager at Palintest Ian Leahy said: "The opportunity to bring our ability to produce rugged, simple-to-use water quality testing kits together with this exciting Molendotech innovation is a perfect example of two organisations collaborating to answer a clear customer need in the markets we already serve. For many years we sought opportunities to deliver simple, real-time microbiological risk screening at the point of use and I'm excited to say we are finally at that point now."

 

 

For more product details, please contact ian.leahy@palintest.com

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP and the University of Plymouth:

Frontier IP has forged a strong relationship with the University of Plymouth to commercialise intellectual property. Other collaborations include:

· Fieldwork Robotics: developing advanced soft robotics for harvesting fruit and vegetables. The technology has attracted strong industry interest.

· The Vaccine Group: work includes creating novel vaccines to prevent viruses from jumping the species barrier from animals to humans

· Pulsiv Solar: US and European patents granted on its novel technology to improve the energy efficiency of photovoltaic cells and power conversion

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGIGDUUXBBGIS
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.